EP4 receptor selective agonists in the treatment of osteoporosis
AssigneePfizer Inc.
InventorsKimberly O. Cameron, Bruce A. Lefker
Life of this patent
Estimating the term…
Abstract
This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.
Claims11
A compound of the formula I
- a prodrug thereof, a pharmaceutically acceptable salt of said compound or said prodrug or a stereoisomer or diastereomeric mixture of said compound, prodrug or salt, wherein:
- the dotted line is a bond or no bond;
- X is O;
- Z is phenyl;
- Q is carboxyl, (C1-C4)alkoxylcarbonyl or tetrazolyl;
- R2 is Ar;
- Ar is Cyclohexyl, 1,2benxodioxolyl, napthyl or phenyl;
- wherein said Ar moeity is optionally substituted with one or two (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl,chloro, fluoro, phenoxy, phenyl or cyano;
- wherein said (C1-C4)alkyl, (C1-C4)alkoxy, or (C1-C4)alkoxy(C1-C4)alkyl substituents in the definition of Ar are optionally substituted on carbon with one to three fluoro.
Dependencies are inferred from the claim text.